Ovarian cancer is generally diagnosed at a late stage, after the disease has spread and has poor survival diagnosis. Currently, there are no effective early detection strategies and early disease symptoms are non-specific (e.g., bloating, feeling of fullness). Biomarkers evaluated to date, do not outperform the “best available” marker CA125; however, a preliminary study provided evidence that a serum microRNA profile may provide better differentiation between ovarian cancer cases and non-cases than CA125. This study will provide validation of a microRNA panel for early detection of ovarian cancer in serum samples from prospective cohorts and clinical data and biospecimens. The overarching objective is to validate a serologic microRNA panel that, together with CA125, would have sufficient diagnostic discrimination for early-stage disease to be used as a tool that, complementary to imaging, would allow early diagnosis and direction of patients with suspected malignancy to personalised gyn-oncological care.